Table 3. Proportions of patients achieving an HbA1c level < 7% or with treatment failure after adding sulfonylurea or DPP-4 inhibitor to metformin monotherapy.

Variables	MS	MD	p-value	HbA1c level < 8% before prescription		p-value	HbA1c level ≥ 8% before prescription		p-value*
				MS	MD		MS	MD
Number of patients	219	149		104	114		115	35
Proportion of patients achieving: HbA1c level < 7.0% (%)†	53.9	61.7	0.163	63.5	71.9	0.194	45.2‡	28.6§	0.116
Proportion of patients with treatment failure (%)b†	13.2	4.0	0.003	6.7	1.8	0.090	19.1§	11.4‡	0.325

MS, patients with addition of sulfonylurea to metformin monotherapy; MD, patients with addition of DPP-4 inhibitor to metformin monotherapy.

^*p-value from Fisher's exact test; ^†during 3–6 months after prescription; ^‡p < 0.05, ^§p < 0.01 in comparison with the corresponding group with HbA1c level < 8% before prescription.